Abivax: Nine Scientific Presentations on Obebazimod at DDW
Abivax announces nine scientific abstracts concerning obebazimod at the Digestive Disease Week, scheduled from May 2 to May 5, 2026, in Chicago. These data are derived from phase 3 of the ABTECT program and encompass efficacy, tolerance, and patient feedback on ulcerative colitis.
The scientific abstracts presented at the conference cover various areas: the efficacy and tolerance of obebazimod in patients with moderately to severely active ulcerative colitis, early symptom improvement, and outcomes observed in specific patient subgroups. Among the nine presentations are also data related to patient quality of life, including improvements in fatigue and overall quality of life reported at 8 weeks. Two abstracts focus on mechanisms of action: one presents preclinical data showing dual antifibrotic and anti-inflammatory activity, while the other reports changes in microRNA-124 expression and a reduction in inflammatory cytokines in patients.
Keynote and Poster Sessions
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
Almost there! Check your inbox.
A confirmation email has been sent. Click the link to confirm your subscription.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
An oral presentation is scheduled for Monday, May 4, from 10:00 AM to 10:15 AM, focusing on the effect of obebazimod on histological and histological-endoscopic outcomes. Eight poster presentations will take place on Monday, May 4, and Tuesday, May 5, 2026, spread across various thematic sessions: controlled clinical trials, quality of life and psychosocial outcomes, as well as mechanisms of action of therapeutics in chronic inflammatory bowel diseases. The presentations will later be available on the publications page of the Abivax website.
Trésorerie et équivalents de trésorerie de 589,7 millions d'euros au 30/09/2025 ; perte nette de 254,1 millions d'euros sur les neuf mois ; produit net d'ADS d'environ 700,3 millions de dollars (?597,2 M€) en juillet 2025 ; position financière nette de 543,3 millions d'euros ; autonomie financière attendue jusqu'au T4 2027. Hausse significative des dépenses R&D et des charges G&A.
Risks mentioned
Risques inhérents à la recherche et au développement clinique
Risque lié aux décisions des autorités réglementaires (FDA, EMA)
Risque de disponibilité insuffisante de fonds pour couvrir les dépenses d'exploitation futures
Obstacles potentiels au développement clinique et pharmaceutique (données précliniques, CMC, toxicologie, etc.)
Opportunities identified
Avancement des essais de phase 3 d'Obefazimod en rectocolite hémorragique
Présentations 'late-breaking' et résultats favorables communiqués lors de congrès scientifiques
Produit net élevé de l'offre d'ADS prolongeant l'autonomie financière jusqu'au T4 2027
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
